China Regenerative Medicine International Limited (HKG:8158)
Hong Kong · Delayed Price · Currency is HKD 0.2320
+0.0120 (5.45%)
Aug 4, 2026, 11:43 AM HKT
HKG:8158 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 72.06 | 90.62 | 69.49 | 41.54 | 282.9 | |
Revenue Growth | -20.48% | 30.41% | 67.29% | -85.32% | 55.32% |
Cost of Revenue | 30.14 | 32.96 | 50.06 | 3.91 | 215.17 |
Gross Profit | 41.92 | 57.65 | 19.42 | 37.62 | 67.73 |
Selling, General & Admin | 42.36 | 51.52 | 45.54 | 25.82 | 47.45 |
Operating Expenses | 42.36 | 51.52 | 45.54 | 25.82 | 6.09 |
Operating Income | -0.44 | 6.14 | -26.11 | 11.81 | 61.63 |
Interest Expense | -1.2 | -1.13 | -0.98 | -0.78 | -0.74 |
Interest & Investment Income | 17.96 | 17.58 | 0.01 | 0 | 0.01 |
Other Non Operating Income (Expenses) | -1.13 | -4.83 | -80.66 | -3.67 | -1.67 |
EBT Excluding Unusual Items | 15.19 | 17.75 | -107.74 | 7.35 | 59.24 |
Other Unusual Items | - | - | 0.04 | 0.91 | 5.05 |
Pretax Income | 15.19 | 17.75 | -107.7 | 8.27 | 64.29 |
Income Tax Expense | -12.34 | - | - | 3.71 | 12.47 |
Earnings From Continuing Operations | 27.53 | 17.75 | -107.7 | 4.56 | 51.83 |
Net Income to Company | 27.53 | 17.75 | -107.7 | 4.56 | 51.83 |
Net Income | 27.53 | 17.75 | -107.7 | 4.56 | 51.83 |
Net Income to Common | 27.53 | 17.75 | -107.7 | 4.56 | 51.83 |
Net Income Growth | 55.05% | - | - | -91.21% | - |
Shares Outstanding (Basic) | 304 | 304 | 286 | 285 | 285 |
Shares Outstanding (Diluted) | 304 | 304 | 286 | 285 | 285 |
Shares Change | - | 6.23% | 0.34% | - | 77.64% |
EPS (Basic) | 0.09 | 0.06 | -0.38 | 0.02 | 0.18 |
EPS (Diluted) | 0.09 | 0.06 | -0.38 | 0.02 | 0.18 |
EPS Growth | 55.17% | - | - | -91.21% | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 4.02 | 17.68 | 10.52 | -15.03 | -3.83 |
Free Cash Flow Per Share | 0.01 | 0.06 | 0.04 | -0.05 | -0.01 |
Gross Margin | 58.17% | 63.62% | 27.95% | 90.58% | 23.94% |
Operating Margin | -0.61% | 6.77% | -37.58% | 28.42% | 21.79% |
Profit Margin | 38.20% | 19.59% | -154.99% | 10.97% | 18.32% |
Free Cash Flow Margin | 5.59% | 19.51% | 15.13% | -36.17% | -1.35% |
EBITDA | 0.22 | 6.8 | -25.54 | 11.98 | 61.71 |
EBITDA Margin | 0.31% | 7.50% | -36.75% | 28.83% | 21.81% |
D&A For EBITDA | 0.66 | 0.66 | 0.57 | 0.17 | 0.08 |
EBIT | -0.44 | 6.14 | -26.11 | 11.81 | 61.63 |
EBIT Margin | -0.61% | 6.77% | -37.58% | 28.42% | 21.79% |
Effective Tax Rate | - | - | - | 44.90% | 19.39% |